Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property
Silo Pharma said the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application tied to its lead PTSD therapy candidate, SPC-15. The decision strengthens the company’s intellectual property position around the intranasal treatment, which is being developed to help prevent or reduce stress-induced behavioral responses associated with post-traumatic stress disorder.
The Sarasota, Florida-based biotech, which trades on Nasdaq under the ticker SILO, describes SPC-15 as a novel therapeutic designed for intranasal delivery. By securing allowed claims covering both composition and method of use, Silo gains broader protection over how the treatment is formulated and how it may be used in addressing trauma-related symptoms.
For a developmental-stage drugmaker, patent momentum can be as important as clinical progress. A Notice of Allowance from the USPTO signals that the patent office has agreed to grant the application once final administrative steps are completed. In practice, that gives Silo added leverage as it advances SPC-15 through development, supports future licensing discussions, and works to differentiate the asset in a competitive neuropsychiatric treatment landscape.
PTSD remains a major area of unmet medical need, affecting people exposed to combat, assault, accidents, and other traumatic events. Existing treatment options can be limited in effectiveness or slow to act, which has driven interest in alternative delivery methods and fast-acting therapeutics. Intranasal drug delivery, in particular, has attracted attention for its potential to improve onset time and patient convenience.
Silo Pharma has focused its pipeline on novel therapeutics and drug delivery systems, while also highlighting a wholly owned managed AI agent platform as part of its broader technology strategy. The SPC-15 program stands out as the company’s lead asset, making this patent development especially significant for investors watching the biotech’s progress.
While the allowance does not represent regulatory approval or commercialization, it marks a meaningful step in building the legal and strategic foundation around SPC-15. For Silo, the patent news adds another layer of value to a program aimed at one of mental health care’s most challenging conditions.
